Arbitan 150 mg (Tablet)
Unit Price: ৳ 12.05 (3 x 10: ৳ 361.50)
Strip Price: ৳ 120.50
Medicine Details
| Category | Details |
|---|---|
| Generic | Irbesartan |
| Company | Opsonin pharma ltd |
| Also available as |
Indications
- Treatment of essential hypertension
- Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus
Pharmacology
- Angiotensin II receptor antagonist
- Blocks vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors
Dosage & Administration
- Usual recommended initial and maintenance dose is Irbesartan 150 mg once daily
- Can be taken with or without food
- Initiation of therapy with Irbesartan 75 mg could be considered for haemodialysed patients and elderly over 75 years
- In patients insufficiently controlled with Irbesartan 150 mg, the dose can be increased to Irbesartan 300 mg
- Irbesartan is not recommended for use in children and adolescents due to insufficient data on safety and efficacy
Interaction
- Potential interaction with diuretics and other antihypertensive agents
- Contraindicated with potassium supplements and potassium-sparing diuretics
- Potential interaction with lithium and non-steroidal anti-inflammatory drugs
- No significant pharmacokinetic interactions observed with warfarin
- Effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of Irbesartan have not been evaluated
Contraindications
- Contraindicated in concomitant use with aliskiren in patients with diabetes and renal impairment (GFR <60 ml/min)
- Contraindicated during pregnancy
Side Effects
- Diarrhoea
- Fatigue
- Dyspepsia or heartburn
- Dizziness
- Orthostatic hypotension
- Nausea
- Vomiting
- Musculoskeletal pain
- Thrombocytopaenia
- Hyperkalaemia
- Elevated serum creatinine
Pregnancy & Lactation
- Contraindicated in the second and third trimesters of pregnancy
- Not recommended during lactation
- Precautionary measure to not use it during the first trimester of pregnancy
- Not known whether it is excreted in human milk
- Precautions for Intravascular volume depletion
Precautions & Warnings
- Precautions needed for patients with renal artery stenosis, aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy
- Close monitoring of serum potassium in patients at risk for hyperkalaemia
- Special caution for patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy
- Not recommended for patients with primary aldosteronism
- Precautions for patients with severe congestive heart failure or underlying renal disease
- Precautions for excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease
Use in Special Populations
- No dosage adjustment is necessary in patients with impaired renal function
- Consider lower starting dose for patients undergoing haemodialysis
- No dosage adjustment is necessary in patients with mild to moderate hepatic impairment
- Effects of Arbitan both on renal and cardiovascular events were not uniform across all subgroups
- Precautions for patients at risk of hyperkalaemia
- Special caution needed in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy
Overdose Effects
- No toxicity observed in adults exposed to doses of up to 900 mg/day for 8 weeks
- Expected manifestations of overdosage include hypotension and tachycardia; bradycardia might also occur
- No specific information available on the treatment of overdosage
- Suggested measures include induction of emesis and/or gastric lavage
- Arbitan is not removed by haemodialysis
Therapeutic Class
- Angiotensin-II receptor blocker
Storage Conditions
- Store in a cool and dry place
- Protected from light